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Objective: The study objective was to evaluate the feasibility, safety, and early tech-
nical and clinical success rate of a new endovascular device specifically designed for
aortic dissection that has recently become available in Europe.
Methods: From June of 2005 to the present, the Zenith Dissection Endovascular Sys-
tem (William Cook Europe, Bjaerverskov, Denmark) was used in 11 selected patients
(all male, with a median age of 58 years [range, 45–76 years]) with type B chronic
aortic dissection with a compression or collapse of the true lumen. All procedures
were performed under general anesthesia with preoperative cerebrospinal fluid drain-
age in 4 patients. One-step open surgical supra-aortic vessels re-routing was
performed in 6 patients to obtain an adequate proximal landing zone: Left carotid-sub-
clavian artery bypass was performed in 5 patients, and right-to-left common carotid
artery bypass and left subclavian to common carotid artery transposition was per-
formed in 1 patient. Clinical follow-up visits and computed tomography scans were
obtained at 1, 6, and 12 months, and yearly thereafter.
Results: A secondary technical success was obtained in all patients (100%), and 30-
day clinical success was achieved in 10 patients (91%). A type IA entry flow was
observed in 1 patient. No mortality was recorded. Occlusion of visceral/renal arteries,
retrograde dissections, and device-induced tears in the intimal lamellae were not ob-
served. Periprocedural morbidity included temporary renal failure in 1 patient and
postimplantation syndrome with fever and leukocytosis for 23 days in 1 patient. No
cases of paraplegia were recorded. At a median follow-up of 12 months (range, 2–
30 months), we observed a clinical success rate of 91%. No migration of the device
was observed. No late occlusion of the visceral or renal arteries was recorded at fol-
low-up.
Conclusion: The perioperative and short-term follow-up results showed that the Ze-
nith Dissection Endovascular System for the treatment of aortic dissection can be
safely used without affecting the patency of the branches covered by the bare stent.
However, these results need to be validated in a larger group of patients with
a mid-term follow-up.
E
xisting stent graft technology was developed for treatment of aneurysmatic
disease. In the thoracic aorta it should important benefits due to its reduced in-
vasiveness and over the years it has been used also to treat different diseases
such as traumatic transection, intramural hematoma, penetrating aortic ulcer and
especially aortic dissection.1-15
The goal of stent-grafts in aneurysmal disease is to exclude the sac from arterial
pressurization to reduce the risk of rupture. However, aortic aneurysms currently rep-
resent only 60% of cases of the indications for thoracic endovascular aortic repair.16
For aortic dissection, on the other hand, the objectives are less clear-cut; remodeling
and complete healing of the dissected aorta may be obtained in only a fraction of
cases. Accepted goals for endovascular treatment of aortic dissections are the follow-
ing: closure of the primary intimal entry tear, depressurization and thrombosis of the
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CT 5 computed tomography
PLZ 5 proximal landing zone
TEE 5 transesophageal echocardiography
false lumen, and expansion of the true lumen.16 To achieve
the latter end points and avoid further aneurysmal evolution
of the false lumen, stabilization of the intimal flap may play
an important role.17 The movements of the intimal flap and
the continuous motion of the blood in the false lumen clearly
contribute in preventing its thrombosis.
This study evaluates the Zenith Dissection Endovascular
System (William Cook Europe, Bjaerverskov, Denmark),
which uses a series of low radial force bare stents positioned
in the aorta distal to the standard stent-graft that covers the
primary tear. This device is specifically designed to expand
the true lumen, stabilizing the intimal flap, and may be posi-
tioned over the origin of the splanchnic and renal vessels.
Materials and Methods
Patients
From June of 2005 to the present, the Zenith Dissection Endovascu-
lar System was used in 11 nonconsecutive patients with type B
chronic aortic dissection. Indications were transaortic growth
more than 5 mm within 6 months or transaortic diameter more
than 50 mm with a compression and collapse of the true lumen.
All patients were male with a median age of 58 years (range 45–
76 years) (Table 1). Patients’ demographics and risk factors are re-
ported in Table 2. The median maximum transaortic diameter was
55 mm (range 48–71 mm). The median interval between the clinical
presentation of the type B dissection and the endovascular procedure
was 19 months (range 3–29 months).The Journal of ThorDevice Description
The Zenith Dissection Endovascular System is a modular system
that is specifically designed to treat aortic dissection and that con-
sists of a proximal component, the Zenith TX2-P TAA Endo-
vascular Graft, and a distal component, the Zenith Dissection
Endovascular stent (Figure 1).
The proximal component is a 1-piece (cylindric or tapered) endo-
vascular stent-graft that is intended to close the primary entry tear.
The stent-graft is fully stented, covered with polyester fabric, and
contains protruding barbs at a 2-mm stagger at its proximal end
and an internal sealing stent without barbs at its distal end. No prox-
imal or distal bare stent is present. The stent-graft component of the
Zenith Dissection Endovascular System is the same as the proximal
component of the 2-piece system also used for treatment of thoracic
aneurysms. The Zenith TX2-P TAA Endovascular Graft is Confor-
mite´ Europe´enne marked and received approval from the Food and
Drug Administration in the United States in May 2008.18
The distal component is a 1-piece cylindric device made from
self-expanding, stainless-steel Cook Z-stent segments sewn to-
gether with polyester suture and no covering fabric. It is intended
to provide support to the delaminated segments of the dissected
aorta, and the stent has a lower radial force than the TX2
stent-graft. The Zenith Dissection Endovascular stent is available
in only 1 diameter (46 mm) fitting all the aortic diameters and
different lengths. It is currently supplied as a custom-made
device.
Methods
The feasibility of the endovascular procedure and sizing of the stent-
grafts were determined with 64-row multislice computed tomogra-
phy with multiplanar reconstructions. Diagnostic workup included
duplex scanning of the iliac, femoral, carotid, and vertebral arteries
to evaluate the adequacy of remote arterial access sites and assess the
patency of extracranial supra-aortic trunks.
Anatomic endovascular inclusion criteria were as follows:
 primary entry tear more than 20 mm below the innominate ar-
tery (covering the left subclavian artery or the left commonTABLE 1. The Zenith Dissection Endovascular System (William Cook Europe, Bjaerverskov, Denmark) used and supra-aortic
vessels re-routing open procedures
N Sex/age (y) Dissection type Proximal endograft Distal bare stent SAT debranching
1 M/47 Post type A repair ZTEG 2PT 34 3 197 GZSD 46 3 123 Right to left CCB 1 left SCT
2 M/61 Chronic type B ZTEG 2P 36 3 127 GZSD 46 3 164 Left CSB
3 M/47 Chronic type B ZTEG 2PT 38 3 152 GZSD 46 3 164 Bilateral CSB
4 M/45 Subacute type B ZTEG 2P 32 3 200 GZSD 46 3 82 None
GZSD 46 3 164
5 M/72 Chronic type B ZTEG 2P 30 3 140 GZSD 46 3 164 None
ZTEG 2PT 34 3 157
6 M/76 Chronic type B ZTEG 2P 36 3 157 GZSD 46 3 164 Left CSB
7 M/58 Chronic type B ZTEG 2PT 36 3 157 GZSD 46 3 164 Left CSB
8 M/53 Chronic type B ZTEG 2PT 42 3 158 GZSD 46 3 123 None
9 M/65 Subacute type B ZTEG 2PT 34 3 157 GZSD 46 3 164 Left CSB
10 M/64 Chronic type B ZTEG 2P 28 3 152 GZSD 46 3 164 None
11 M/54 Chronic type B ZTEG 2PT 36 3 197 GZSD 46 3 123 None
SAT, Supra-aortic trunk; ZTEG, Zenith thoracic endograft; 2P, TX2 proximal cylindrical; 2PT, TX2 proximal tapered; GZSD: Gianturco Z-stent dissection, CCB,
carotid-to-carotid bypass; SCT, subclavian to carotid transposition, CSB, carotid to subclavian bypass.acic and Cardiovascular Surgery c Volume 136, Number 4 1013
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branching and revascularization);
 primary entry tear more than 20 mm above celiac trunk;
 proximal landing zone (PLZ) diameter for stent-graft, mea-
sured from outer wall to outer wall on a sectional image or
multiplanar reconstruction more than 24 mm and less than
38 mm, respectively;
 distal landing zone diameter for stent-graft, measured outer
wall to outer wall on a sectional image or multiplanar recon-
struction more than 24 mm (estimate based on transaortic di-
ameter) or less than 38 mm (estimate based on true lumen
diameter); and
 any segment of vessel into which deployment of bare stent
device is intended measuring more than 24 mm (estimate
based on transaortic diameter) or less than 38 mm (estimate
based on true lumen diameter).
All procedures were performed in the operating room under
general anesthesia, using a portable digital C-arm image intensifier
and intraoperative transesophageal echocardiography (TEE). Pre-
operative cerebrospinal fluid drainage was used in 4 patients. In
6 patients, supra-aortic vessels re-routing was performed before
the stent-graft deployment to obtain an adequate PLZ: 4 cases of
left carotid-subclavian artery bypass for zone 2 PLZ, 1 case of bi-
lateral carotid-subclavian artery bypass for right aberrant subcla-
TABLE 2. Patients' demographics and risk factors
Risk factors N









Previous ascending aorta repair 31014 The Journal of Thoracic and Cardiovascular Surgery c Ocvian artery, and 1 case of right to left common carotid artery
and left subclavian to common carotid artery transposition for
zone 1 PLZ (Table 1).
The common femoral artery, exposed through an inguinal inci-
sion, was used as the remote access vessel in all patients. An initial
aortography to assess the patency of visceral vessels and their origin
from the true and false lumens was performed. A superstiff Lunder-
quist precurved guidewire (Cook Inc, Bloomington, Ind) was placed
over a pigtail catheter navigated in the true lumen, under both fluo-
roscopic and TEE guidance, to ensure definite positioning of the stiff
wire in the true lumen, which is essential for correct deployment of
the stent-graft. The Zenith TX2-P stent-graft (Table 1) was carefully
advanced over the stiff wire and deployed in the intended position.
Aortography and TEE were then performed to ensure correct exclu-
sion of proximal entry tear. The Zenith Dissection Endovascular
Stent (Table 1) and its delivery system were then inserted through
the same sheath and wire used for deployment of the proximal com-
ponent. The stent was then advanced in the planned location and
deployed overlapping 1 stent with the proximal stent-graft. Balloon-
ing of the bare stent device was not performed. Final angiography
and TEE completed the procedure. Careful angiographic evaluation
of the patency of visceral and renal arteries was performed in all
patients.
Success Measures, Follow-up Protocol, and Statistical
Analysis
The reported results and methods are in accordance with the current
reporting standards for endovascular aortic repair prepared and
revised by the Ad Hoc Committee for Standardized Reporting Prac-
tices in Vascular Surgery (Society for Vascular Surgery/American
Association for Vascular Surgery).19 Patients were evaluated with
postprocedure chest x-ray and contrast computed tomography
(CT) scans with scheduled follow-up imaging at 1, 6, and 12
months, and yearly thereafter. Angiograms were obtained in
selected cases. Clinical follow-up was also done at regular intervals
of 6 months. Data are shown as number (%) for categoric variables
or as median, first quartile, and third quartile (Q1-Q3) and mean for
continuous variables, because they did not show a Gaussian distri-
bution. Analyses were performed with SAS v8 software (SAS Insti-
tute Inc, Cary, NC).Figure 1. A, Preoperative 3-dimensional CT scan
of a case of type B aortic dissection with proximal
neck located on zone 2. B, Postoperative 3-dimen-
sional CT scan after a left carotid-subclavian ar-
tery bypass and successful deployment of the
Zenith Dissection Endovascular System (William
Cook Europe, Bjaerverskov, Denmark). Note the
complete thrombosis of proximal and mid-tho-
racic false lumens with reexpansion of the true
lumen and reperfusion of the distal thoracic false
lumen because of presence of reentry tears.tober 2008
Melissano et al Evolving TechnologyFigure 2. A, One-month postoperative
CT scan of a case of type B aortic dis-
section showing a type II reentry flow
from a previous revascularized left sub-
clavian artery (arrow). B, Retrograde
angiogram from the left subclavian ar-
tery showing complete false lumen per-
fusion. C, Predischarge CT scan after
procedure of endovascular occlusion
of the origin of the left subclavian artery
with an Amplatzer plug (AGA Medical,
Golden Valley, MN, USA) showing com-
plete thrombosis of false lumen with
resolution of the type II reentry flow.ETResults
The primary entry tear was located just distal to the subcla-
vian artery in 9 cases, in one case it was located at the
2 mm above the left subclavian artery and in the case of right
aberrant subclavian artery the vessel origin was directly in-
volved by the dissection. The dissection extended down
into 1 (9 cases) or both (2 cases) iliac arteries. The false lumen
was patent in all cases. The branch vessels were compro-
mised by an exclusively dynamic process in all cases, and
no branch vessels originated from the false lumen. The me-
dian diameter of the landing zone for the Zenith TX2-P
TAA Endovascular Graft was 32 mm (range 26–37 mm)
proximally and 22 mm (range 16–27 mm) distally, estimated
on the basis of the true lumen diameter. The smaller segment
of vessel into which the deployment of the bare stent was per-
formed was 14 mm (range 12–24 mm), estimated on the basis
of the true lumen diameter.
TEE evaluation performed 10 to 15 minutes after Zenith
TX2 TAA Endovascular Graft deployment showed a com-
plete spontaneous echo-contrast effect, the so-called
‘‘smoke’’ phenomenon,20 in 9 patients (82%). In 1 patient,
persistent perfusion of the false lumen caused by type IA
endoleak was successfully treated with proximal ballooning.
In 1 patient, a type IB peri-stent leak with a pulsed Doppler
velocity greater than 50 cm/sec caused by a distal reentry
tear was treated with an adjunctive Zenith TX2-P stent-graft.
In all patients, completion angiography demonstrated com-
plete exclusion of the proximal entry tear and TEE showed
complete spontaneous echo-contrast effect, with a rate of sec-
ondary technical success of 100%. No occlusion of the vis-
ceral or renal artery was recorded. No additional surgical or
endovascular procedures were necessary.
No 30-day mortality was recorded in this series. The me-
dian intensive care unit stay was 1 day (range 1–2 days).
Clinical success was observed in 10 patients (91%); 1 case
of type IA entry flow was observed at predischarge CT
scan. Left subclavian artery percutaneous occlusion was per-The Journal of Thorformed as an adjunctive procedure to correct a type II entry
flow in 1 patient (Figure 2). A type II entry flow from an in-
tercostal artery was observed in 1 patient, who was treated
conservatively.
Periprocedural morbidity (30-day) included 1 case of
serum creatinine increase more than 30% versus the prepro-
cedure values and 1 case of postimplantation syndrome. The
patient had fever, leukocytosis, and increased biochemical
inflammatory markers without evidence of sepsis or infec-
tion, which resolved after corticosteroids administration on
the 24th postoperative day. No cases of paraplegia were
recorded. The median in-hospital stay was 4 days (range 2–
6 days).
At amedian follow-up of 11.7months (range2–30months),
we observed a clinical success rate of 91% (10/11 cases): spon-
taneous resolutionof the procedural type I entryflowand1 case
of false lumen enlargement of 4 mm. No migration of the Ze-
nith Dissection Endovascular Systemwas observed. No occlu-
sion of the visceral or renal arteries was recorded.
The false lumen showed different characteristics in the
thoracic segment than in the celiac segment. Where the
Zenith TX2 TAA Endovascular Graft was deployed, throm-
bosis of the false lumen was observed in all patients, with
shrinkage of the false lumen in 4 patients, no change in 6 pa-
tients, and false lumen enlargement of 4 mm in 1 patient.
Where the Zenith Dissection Endovascular stent was
deployed, false lumen thrombosis was not observed and there
was no shrinkage (.5 mm). However, in all cases, a median
reexpansion of the true lumen of 5 mm (range 2–7 mm) with-
out any change of the transaortic diameter was observed.
Discussion
Stent-graft repair of descending thoracic aortic aneurysms
currently offers encouraging outcomes when compared
with those of open surgery.1,2,4 Stent-grafts have been used
to treat dissections since the 1990s; however, the effective-
ness of this procedure remains unproven for patients withacic and Cardiovascular Surgery c Volume 136, Number 4 1015
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dissection.
The rationale of endovascular treatment for aortic dis-
section is based on the exclusion of the false lumen
from the circulation. In chronic dissections, the graft
does not immediately compress the dissection membrane
against the aortic wall as in acute dissections. However,
the closure of the primary entry tear redirects the blood
flow into the true lumen, thus decompressing the false lu-
men. As a result of the effective obliteration of the primary
entry tear, a state of low turbulent flow in the thoracic por-
tion of the false lumen was evident in all our patients at
TEE. Despite heparinization, initial thrombosis was ob-
served in 9 patients and postoperative CT showed throm-
bosis of the proximal descending thoracic false lumen in
10 patients.
Complete healing of a chronic dissection may be expected
in only a fraction of cases; healing requires some time and has
relevant prognostic consequences. Recent insights on the nat-
ural history of chronic dissections showed partial thrombosis
of the false lumen to be a strong independent predictor of
mortality.21 This may be related to an increased pressure in
the false lumen, secondary to the occlusion of distal tears
that impedes outflow, resulting in a blind sac that may cause
further aneurysmal dilatation, re-dissection, or rupture.
Accepted goals of simple exclusion of proximal entry tear
are decompression of the thoracic false lumen and promotion
of proximal thrombosis and remodeling of the false lumen.
However, the distal thoracic and abdominal dissected aortas
fails to remodel in 50%–80% of cases,15 probably due to
both distal communication sites between the true and false lu-
mens and the flapping motion of the dissecting lamella, which
prevents complete false lumen thrombosis. Aortic remodeling
may fail with this limited approachwith consequent risk of fur-
ther aneurysmal expansion, extension of the dissection, or rup-
ture. Aggressive management of distal thoracic entry tears by
means of adjunctive stent-grafts deployment above the celiac
trunk could help to enhance false lumen thrombosis. However,
the risk of spinal cord ischemia increaseswith a stent-graft cov-
erage longer than 20 cm.22Moreover, true lumen compression
at the level of the abdominal aorta and consequent visceral
branchmalperfusionare not fully addressedwith this approach.
Ito and colleagues23 reported a case of type B aortic dis-
section with malperfusion that was successfully treated
with implantation of a Gianturco Z-stent (Cook, Inc.,
Bloomington, IN) in the distal thoracic and abdominal aorta.
Nienaber and colleagues17 proposed the Provisional Exten-
sion to Induce Complete Attachment (the PETTICOAT Con-
cept) to treat distal true lumen collapse and a perfused
abdominal false lumen despite successful stent-graft sealing
of the proximal tears. The authors successfully placed
a bare metal scaffolding stent for distal extension of the pre-
viously implanted stent-graft (as an adjunctive or staged pro-
cedure) in 12 patients, achieving the re–expansion of the true1016 The Journal of Thoracic and Cardiovascular Surgery c Olumen and resolution of malperfusion in all cases. In this se-
ries, sinus aortic stent (Optimed Medizinische Instrumente
GmbH., Ettlingen, Germany) and Fortress stents (Curative
Medical Devices Inc., Dresden Germany) were used in 11
patients and the Zenith Dissection Endovascular stent was
used in 1 patient.
Mossop and colleagues24 recently reported the treatment
of 7 patients with type B acute aortic dissection with stent-
graft (Zenith TX2 TAA Endovascular Graft) closure of the
proximal entry tear and a bare metal Z-stent deployed in
the residual delaminated aorta. They used Gianturco Z-stents
in 3 patients and the Zenith Dissection Endovascular stent in
4 patients, achieving a mean immediate abdominal true
lumen expansion greater than 130% in all patients. No
long-term adverse events related to Z-stent implantation,
including stent migration, fracture, intimal flap erosion, or re-
dissection, were reported.
The possible detrimental effects of bare stent struts
extended to or above the level of renal or visceral arteries
have been investigated for endovascular treatment of infrare-
nal aortic aneurysms with stent-graft with suprarenal fixation.
The majority of these studies observed no adverse effect of
suprarenal fixation on renal function at mid-term follow-up
and no visceral artery perfusion impairment.25,26
In our study, we used the complete Zenith Dissection En-
dovascular system in all patients. At follow-up, we observed
a successful proximal thrombosis of the false lumen in all
patients and enlargement at 12 months despite exclusion of
the false lumen in 1 patient (9%). No adverse events related
to the Zenith Dissection Endovascular Stent were observed.
A median rate of reexpansion of the true lumen of the distal
thoracic and abdominal aorta of 5 mm was detected. Mossop
and colleagues24 reported an increase in the mean abdominal
aortic true lumen index (true lumen area/total aorta area) from
41% 6 17% (standard deviation) to 75% 6 14% (standard
deviation) with the Zenith Dissection Endovascular stent.
The lower rate of re–expansion reported may be explained
by the different timing of treatment of the aortic dissection
in our study (chronic vs acute).
Retrograde type A dissection is a potentially lethal com-
plication of endovascular stent-graft repair that may occur
as immediate or delayed.27,28 In our previous experience,
an acute retrograde dissection developed in a patient 3 days
after undergoing endovascular repair of an acute type B dis-
section with a proximal bare stent endograft, leading to myo-
cardial infarction, pericardial tamponade, and death.29
Several factors are believed to play a role in the development
of such a complication.30 In particular, the presence of prox-
imal uncovered bare stents or bare springs with high radial
force may lead to an injury of the intima.31,32
The proximal component of the Zenith Dissection Endo-
vascular System used in our study contains protruding barbs
at a 2-mm stagger at its proximal end without a proximal bare
stent. In our experience, we did not observe retrogradectober 2008
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has an internal sealing stent without barbs, as well as the
Zenith Dissection Endovascular Stent. This peculiar charac-
teristic is important to avoid damage of the dissecting lamella
in the distal descending thoracic and abdominal aorta. More-
over, a tapered proximal stent-graft reduces the oversize in
the dissected aorta and avoids device-induced tears or
dissection.
Endovascular stent-grafting has recently become an alter-
native treatment option in patients with type B aortic dissec-
tions. Recent reports confirmed the safety and efficacy in
terms of 1-year survival in comparison with medical therapy
and surgery.33 The effectiveness of endovascular therapy is
secondary to reduced procedure time, low rate of bleeding,
intraoperative complications, and lower associated morbid-
ity. The final objective of stent grafting is represented by
depressurization with thrombosis of the false lumen. Patency
of the false lumen was reported to be a predictor of outcome
in patients with type B aortic dissection. Several studies have
suggested an improved outcome in patients with complete
thrombosis of the false lumen and an increased risk of com-
plications and death because of aortic expansion in patients
with a patent false lumen.34
Conclusions
Our perioperative and short-term follow-up results with the
use of the Zenith Dissection Endovascular System device
for the treatment of aortic dissection in a small group of se-
lected patients showed that, in this clinical setting, the device
can be safely inserted without significantly modifying the op-
erating time and morbidity or affecting the patency of the
branches that were covered by the bare stents. All patients
survived; a stable or improved situation of the dissected aorta
was achieved in 10 of 11 patients. The continued need for
surveillance is obviously still mandatory. Also, preliminary
results in different clinical settings should be evaluated
before a more widespread use of the device can be suggested.
We acknowledge Dr Giuseppe Crescenzi, from the Department
of Cardiovascular Anesthesia and Intensive Care of San Raffaele
Hospital, for performing TEE evaluation during all the procedures
of the study, and Dr Gliliola Calori, from the Statistical Unit of
San Raffaele Hospital, for help with the statistical analysis of the ar-
ticle’s data.
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